Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators

被引：50

作者：

Elmore, SW ^{[1
]}

Pratt, JK

Coghlan, MJ

Mao, Y

Green, BE

Anderson, DD

Stashko, MA

Lin, CW

Falls, D

Nakane, M

Miller, L

Tyree, CM

Miner, JN

Lane, B

机构：

[1] Abbott Labs, Abbott Pk, IL 60064 USA

[2] Ligand Pharmaceut Inc, New Leads Discovery & Transcript Res, San Diego, CA 92121 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 07期

关键词：

D O I：

10.1016/j.bmcl.2004.01.044

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The SAR at C-5 of the 10-methoxy-2,2,4-trimethylbenzopyrano[3,4-f]quinoline core leading to identification of (-) anti 1-methylcyclohexen-3-yl as the optimum substituent that imparts minimal GR mediated in vitro transcriptional activation while maintaining full transcriptional repression is described. The in vitro profile of these candidates in human cell assays relevant to the therapeutic window of glucocorticoid modulators is outlined. (C) 2004 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1721 / 1727

页数：7

相关论文

共 40 条

[31] STEROID-HORMONES AND THE CONTROL OF BODY-WEIGHT [J].

REMESAR, X ;

FERNANDEZLOPEZ, JA ;

ALEMANY, M .

MEDICINAL RESEARCH REVIEWS, 1993, 13 (05) :623-631

[32]

Schimmer B., 1996, PHARM BASIS THERAPEU, V9th, P1459

[33] SLE and osteoporosis: Dependence and/or independence on glucocorticoids - Viewpoint [J].

Sels, F ;

Dequeker, J ;

Verwilghen, J ;

MbuyiMuamba, JM .

LUPUS, 1996, 5 (02) :89-92

[34] Nuclear factor-kappa B repression in antiinflammation and immunosuppression by glucocorticoids [J].

vanderBurg, B ;

Liden, J ;

Okret, S ;

Delaunay, F ;

Wissink, S ;

vanderSaag, PT ;

Gustafsson, JA .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1997, 8 (04) :152-157

[35] TRANSCRIPTIONAL INTERFERENCE BETWEEN C-JUN AND THE GLUCOCORTICOID RECEPTOR - MUTUAL INHIBITION OF DNA-BINDING DUE TO DIRECT PROTEIN PROTEIN-INTERACTION [J].

YANGYEN, HF ;

CHAMBARD, JC ;

SUN, YL ;

SMEAL, T ;

SCHMIDT, TJ ;

DROUIN, J ;

KARIN, M .

CELL, 1990, 62 (06) :1205-1215

[36] Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore [J].

Zhi, L ;

Ringgenberg, JD ;

Edwards, JP ;

Tegley, CM ;

West, SJ ;

Pio, B ;

Motamedi, M ;

Jones, TK ;

Marschke, KB ;

Mais, DE ;

Schrader, WT .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (12) :2075-2078

[37] Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators [J].

Zhi, L ;

Tegley, CM ;

Pio, B ;

Edwards, JP ;

Jones, TK ;

Marschke, KB ;

Mais, DE ;

Risek, B ;

Schrader, WT .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (12) :2071-2074

[38] 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators [J].

Zhi, L ;

Tegley, CM ;

Pio, B ;

Edwards, JP ;

Motamedi, M ;

Jones, TK ;

Marschke, KB ;

Mais, DE ;

Risek, B ;

Schrader, WT .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (19) :4104-4112

[39] 5-alkyl 1,2-dihydrochromeno[3,4-f]quinolines:: A novel class of nonsteroidal progesterone receptor modulators [J].

Zhi, L ;

Tegley, CM ;

Edwards, JP ;

West, SJ ;

Marschke, KB ;

Gottardis, MM ;

Mais, DE ;

Jones, TK .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (23) :3365-3370

[40]

1976, NUTR REV, V34, P185

← 1 2 3 4 →